The Testosterone Saga

Monday, Jul 17, 2017
  • Testosterone Replacement Therapy Medical Record Review & Outsourcing Services

Testosterone Replacement products were silent players of the pharma industry dating back to 1950. Manufacturers such as Allergan, Endo Pharmaceuticals had their heels dug in, but it was a slump until  AndroGel, a brand by  AbbVie entered the market with a boom in  2011. A year earlier in 2010,  Eli Lilly had launched  Axiron, but it was AbbVie who introduced the term "Low-T" to the world.

Low testosterone actually means a decrease in testosterone hormone levels in males, which is common after the age of 50. AbbVie specifically targeted this age group to create a superfluous market. People were now concerned about low testosterone levels, and AndroGel was portrayed as a miracle product until the day a realization dawned that Testosterone therapies are actually triggering cardiovascular risks, stroke, and even death in men.

Table of  TRT products and their manufacturers

Name Type Manufacturer
Axiron Topical solution Eli Lily
Testim Gel Auxilium
AndroGel Gel AbbVie
Bio-T-Gel Gel Teva
Fortesta, Testopel Gel Endo
Striant Mucoadhesive Columbia



FDA approves first testosterone products for them who lack or have low testosterone levels (genetic problems or chemotherapy; and problems with the hypothalamus and pituitary brain structures)


Axiron Launched by Eli Lilly

2011 04/29

Abbott announces that the FDA has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless, gel formulation, patented till 2015.

2011 10/19

Abbott separates AbbVie as a business initiative and plans it would operate as a research-based pharmaceutical manufacturer, so it is AbbVie the manufacturer for AndroGel from here on

Extensive campaigning through an unbranded promotion (the site) and awareness-first TV spots. 'Drive for Five' campaign by AbbVie urged men to know their numbers including cholesterol, blood pressure, blood sugar, Prostate-specific antigen- PSA, and testosterone.

49% market share by AndroGel, increased to 65% in later years.


$1 billion sales mark in nine months; 3.3 million scripts dispensed.

Up to 2014  

AndroGel sales and usage keeps increasing along with Axiron manufactured by Eli Lilly which was following the same trail as AndroGel.

2013 -2014 June

Research studies suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy


AbbVie's AndroGel patent expires.


Top players feel the downward sale figures because of patent expiry, perceived risk of cardiovascular or metabolic disease owing to the consumption of TRT products and FDA safety warning issued.

2016 10/25

FDA approves new changes to testosterone labeling regarding the risks associated with abuse and dependence of testosterone and other anabolic androgenic steroids (AAS) as it is associated with serious safety risks affecting the heart, brain, liver, mental health, and endocrine system.

2017 10/25

FDA approves new changes to testosterone labeling regarding the risks associated with abuse and dependence of testosterone and other anabolic androgenic steroids (AAS) as it is associated with serious safety risks affecting the heart, brain, liver, mental health, and endocrine system.

2017 03/01

Perrigo announces FDA's final approval for the generic version of Axiron® Topical Solution, 30 mg/1.5 mL

2014 06/05

AbbVie Inc., the first manufacturer to face trial was whose product AndroGel was the most widely used type of testosterone replacement therapy. The first AbbVie bellwether trial, held on 06/05/2017, was declared as a mistrial. However, 5 other dates have been scheduled for the forthcoming trials: 7/17/2017, 8/28/2017, 10/9/2017, 11/20/2017, and 1/8/2018

With over 7,000 cases filed against the manufacturers of Testosterone Replacement Therapy (TRT) in the federal court system, this is a certainly one amongst the top Mass tort litigations. This suit alleges lapse on the part of the manufacturer to issue adequate warnings about the risks of the product, these risks include serious medical conditions such as increased risks of heart attacks, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE).

The trial buzz is on and affected claimants are still contacting law firms to associate with the MDL. Intaking cases is of utmost importance to a law firm, at the same time validating them by way of a thorough review of records to ascertain Proof of Usage (POU) and Proof of Injury (POI) is of equal significance. Evidence to be looked for in potential Low-T cases: Indication of Testosterone usage in Medical Records; Evaluation of Risk and Confounding factors from Past Medical History; Pharmacy records indicating usage of Testosterone Sticker labels of Testosterone gels; Duration/Formulation of Testosterone usage; Follow-up complications and their treatment after initiation of Testosterone therapy in medical records.

For more information, on other Mass Torts please click here. You may email us at or call +1-844-NIT-TEAM (648-8326).

We are social:



Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...


NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...



CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...


CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...


NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

Rewards & Recognition Program - July 2019
Neural IT organized ‘Rewards & Recognition Program' on July 5, 2019, to motivate employees an
International Yoga Day - Image - Neural IT
International Yoga Day celebrated at Neural IT to bring physical and emotional health for our tea
MTMP April 2019
Neural IT shared presence with Mike Papantonio at the spectacular 3-day conferenc

Latest Tweets